Resistant GIST and redefining the role of F18 FDG PET

Abstract

We herein explore the potential additional value of F18 FDG PET scans in the management of GIST, given the prompt metabolic response to targeted molecular therapeutic drug - Imatinib and newer drugs. Literature review on the molecular pathogenesis of the primary tumor and primary and secondary resistance to Imatinib therapy could pave the way for the potential use of F18 FDG PET scan in assessing and predicting early metabolic response, acquired resistance and prognostication in these tumors. This report highlights the various areas of clinical potential and the need for prospective studies to redefine and extend the role of F18 FDG PET scans in GIST.